Highly active agonistic CD4 binding site anti-HIV antibodies (HAADS) comprising modified CDRH2 regions that improve contact with gp120
US10590187B2 · kind B2 · utility
1Cited by
9References
5Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Dec 21, 2017 |
| Grant date | Mar 17, 2020 |
| Priority date | — |
| Expiry date | Dec 21, 2037 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2740/16111
- WIPO fieldBiotechnology
- WIPO sectorChemistry
Abstract
Embodiments of the present invention are directed to compositions and methods for anti-HIV (anti-CD4 binding site) potent VRC01-like (PVL) antibodies targeted to gp120 having an amino acid substitution at a residue in the anti-CD4 binding site PVL antibody that is equivalent to Phe43 in CD4, these antibodies having improved potency and breadth.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.